Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

Stopped Vandetanib is no longer available as Sanofi has decided not to provide additional drug. All subjects are off-study.

Conditions

• Renal Cell Carcinoma
• Hereditary Leiomyomatosis
• Renal Cell Cancer

Interventions

• DRUG: Vandetanib
• DRUG: Metformin
• DRUG: Vandetanib/Metformin

Sponsor

National Cancer Institute (NCI)